UC San Diego Moores Cancer Center Launches Brain Tumor Trial- Tocagen
This video introduces Dr. Santosh Kesari and his patient.
UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a San Diego Company, Tocagen Inc.
This video introduces Dr. Santosh Kesari and his patient.
UC San Diego Moores Cancer Center researchers and surgeons are among the first in the nation to treat patients with recurrent brain cancer by directly injecting an investigational viral vector into their tumor. The treatment is being developed by a San Diego Company, Tocagen Inc.
“This clinical trial targets glioblastoma — one of the deadliest forms of brain tumor” said principal investigator Santosh Kesari, MD, PhD, Director of Neuro-Oncology in the Moores Cancer Center and in the Department of Neurosciences at the University of California, San Diego. “Clinical trials of investigational therapies such as this may lead to new treatment options for patients battling this deadly disease.”
